Last reviewed · How we verify
PYY3-36
At a glance
| Generic name | PYY3-36 |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP (NA)
- APPETITE: linguAl PYY3-36 on aPpEtite and acuTe Energy InTakE
- High Quality Protein for Assisting With Weight Loss (NA)
- A Dose Escalating Study to Assess the Safety and Tolerability of GT-001 (PHASE1)
- Breakfast Intake and Satiety Hormones (NA)
- Degradation of the Anorexic Hormone Peptide YY (EARLY_PHASE1)
- Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism. (NA)
- The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PYY3-36 CI brief — competitive landscape report
- PYY3-36 updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI